Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Nautilus Biotechnology, Inc.

NAUT · Nasdaq · CIK 0001808805 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

2 Form 4 transaction lines observed in the same window
2 sales · 0 option, withholding, award, gift or other lines

Last qualifying purchase2026-03-04 · Patel Sujal M · $65.2K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
AH Bio Fund II, L.P.; AH Equity Partners Bio II, L.L.C.; AH Equity Partners LSV II, L.L.C.; Andreessen Horowitz LSV Fund II, L.P.; Andreessen Marc L; HOROWITZ BENJAMIN ATenPercentOwner
▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-03-04 · Patel Sujal M.

Recent Form 4 activity

2Purchases
2Sales
0Other Form 4 lines
3SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
5,771,054
Previous report
4,082,014
Avg daily volume
4,066,706
Days to cover
1.4

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-03-04Patel Sujal MPurchase (P)Common Stock25,000USD 2.61USD 65,250SEC filing ↗
2025-11-06Suzuki KentaroPurchase (P)Common Stock4,000USD 1.49USD 5,960SEC filing ↗
2025-09-08Patel Sujal MPurchase (P)Common Stock83,500USD 0.68USD 56,780SEC filing ↗
2025-09-05Patel Sujal MPurchase (P)Common Stock116,500USD 0.67USD 78,055SEC filing ↗
2025-09-04Murphy Matthew B.Purchase (P)Common Stock20,000USD 0.64USD 12,800SEC filing ↗
2025-05-29Mowry AnnaPurchase (P)Common Stock15,000USD 0.77USD 11,550SEC filing ↗
2025-05-12Mallick ParagPurchase (P)Common Stock1,500USD 0.73USD 1,095SEC filing ↗
2025-05-08Mallick ParagPurchase (P)Common Stock12,000USD 0.73USD 8,760SEC filing ↗
2025-03-20Patel Sujal MPurchase (P)Common Stock23,933USD 1.00USD 23,933SEC filing ↗
2025-03-19Patel Sujal MPurchase (P)Common Stock53,300USD 0.99USD 52,767SEC filing ↗
2024-03-11Patel Sujal MPurchase (P)Common Stock12,044USD 2.84USD 34,205SEC filing ↗
2024-03-08Patel Sujal MPurchase (P)Common Stock2,430USD 2.99USD 7,266SEC filing ↗
2024-03-07Patel Sujal MPurchase (P)Common Stock18,854USD 2.89USD 54,488SEC filing ↗
2024-03-06Patel Sujal MPurchase (P)Common Stock9,267USD 2.70USD 25,021SEC filing ↗
2024-03-05Patel Sujal MPurchase (P)Common Stock7,405USD 2.65USD 19,623SEC filing ↗

Form 4 evidence

4 transaction lines in the latest 365-day window; 62 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-02AH Bio Fund II, L.P.; AH Equity Partners Bio II, L.L.C.; AH Equity Partners LSV II, L.L.C.; Andreessen Horowitz LSV Fund II, L.P.; Andreessen Marc L; HOROWITZ BENJAMIN ASale (S)Common Stock5,000,000USD 2.35USD 11,750,000SEC filing ↗
2026-03-04Patel Sujal MPurchase (P)Common Stock25,000USD 2.61USD 65,250SEC filing ↗
2025-11-06Suzuki KentaroPurchase (P)Common Stock4,000USD 1.49USD 5,960SEC filing ↗
Show recent Form 4 evidence (3 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-02AH Bio Fund II, L.P.; AH Equity Partners Bio II, L.L.C.; AH Equity Partners LSV II, L.L.C.; Andreessen Horowitz LSV Fund II, L.P.; Andreessen Marc L; HOROWITZ BENJAMIN ASale (S)Common Stock5,000,000USD 2.35USD 11,750,000SEC filing ↗
2026-03-04Patel Sujal MPurchase (P)Common Stock25,000USD 2.61USD 65,250SEC filing ↗
2025-11-06Suzuki KentaroPurchase (P)Common Stock4,000USD 1.49USD 5,960SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerNAUT
CIK0001808805
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC3826 Laboratory Analytical Instruments
ExchangeNasdaq

Data coverage

Local Form 4 history62 transaction lines from 2020-08-11 to 2026-06-02
46 P purchase lines · 4 S sale lines · 12 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.